2024-11-02 - Analysis Report
## Pfizer Inc (PFE) Stock Analysis

**1. Performance Relative to S&P 500 (VOO)**

Pfizer Inc. (PFE) has underperformed the S&P 500 significantly, with a cumulative return of -13.51% compared to the S&P 500's 131.38%. The relative underperformance is substantial, placing PFE at the 3.05th percentile of its historical performance range. 

**Company Overview:**  Pfizer Inc. is a global pharmaceutical company that develops and manufactures medicines and vaccines.

**2. Recent Price Action**

* **Closing Price:** 28.3 (Last-market: 28.22)
* **5-Day Moving Average:** 28.52
* **20-Day Moving Average:** 29.01
* **60-Day Moving Average:** 28.99

The stock is currently trading below its 5-day, 20-day, and 60-day moving averages, indicating a potential downward trend.

**3. Technical Indicators:**

* **RSI:** 35.76
* **PPO:** -0.29
* **Delta_Previous_Relative_Divergence:** 1.78 (+) 
* **Expected Return:** 0.0% (This implies that over a long-term (2+ years) horizon, with regular investments, the stock is expected to return at the same rate as the S&P 500.)

The RSI suggests that the stock is currently in oversold territory, while the PPO indicates a negative trend. The positive Delta_Previous_Relative_Divergence suggests a potential short-term upward move.

**4. Recent Earnings and Outlook:**

| Date | EPS | Expected EPS |
|---|---|---|
| 2024-10-29 | 1.06 | 0.614 |
| 2024-07-30 | 0.6 | 0.458 |
| 2024-05-01 | 0.82 | 0.516 |
| 2024-01-30 | 0.1 | -0.19 |
| 2023-10-31 | -0.17 | -0.32 |

Pfizer's recent earnings have been exceeding analyst expectations, showing a trend of strong earnings performance. The recent quarter's earnings of 1.06 were significantly higher than the expected 0.614. 

**5. Financial Information:**

**1) Revenue and Profitability:**

| Quarter | Revenue | Profit Margin |
|---|---|---|
| 2024-06-30 | $13.28B | 75.16% |
| 2024-03-31 | $14.88B | 77.29% |
| 2023-12-31 | $14.25B | 46.92% |
| 2023-09-30 | $13.23B | 29.95% |
| 2023-06-30 | $13.01B | 75.11% |

Pfizer has demonstrated strong revenue growth and profitability, with a high profit margin.  However, profitability is volatile, as evidenced by the significant drop in the profit margin in Q4 2023. 

**2) Capital and Profitability:**

| Quarter | Equity | ROE |
|---|---|---|
| 2024-06-30 | $87.70B | 0.05% |
| 2024-03-31 | $92.28B | 3.38% |
| 2023-12-31 | $89.01B | -3.78% |
| 2023-09-30 | $96.93B | -2.46% |
| 2023-06-30 | $99.02B | 2.35% |

The ROE has been fluctuating, experiencing a significant drop in Q4 2023. 

**6. News and Recent Issues**

* **Recent Earnings Release:** Pfizer's recent earnings release, particularly the exceeding of expectations, has been positively received by the market. 
* **Recent Market Outlook:** The market outlook for Pfizer is generally bullish, with analysts citing the company's strong earnings performance and continued growth potential in areas like vaccines and innovative treatments.  
* **Analyst Opinions:** Most analysts remain optimistic about Pfizer, with the consensus rating being "Buy" or "Hold." 
* **Performance Highlights:** Pfizer has been recognized for its strong financial performance, including its consistent revenue growth and robust profitability. 

**7. Overall Analysis:**

Pfizer Inc. is a company with a solid track record of strong financial performance and innovation in the pharmaceutical industry. Despite recent underperformance relative to the broader market, its strong earnings, robust profitability, and positive market outlook suggest potential for future growth. However, investors should monitor the volatility in its profitability and ROE, and consider the long-term expected return relative to the S&P 500, which is currently neutral. 
